.. .. Patients,

. .. Histologie,

. .. Immunohistochimie,

. .. Analyses-statistiques,

. .. Resultats,

. .. Courbes-de-survie,

. .. Discussion,

. .. Conclusion,

. References and . .. Bibliographiques,

. .. Annexes,

.. .. Abréviations, Annexe, vol.1

, Annexe 2. Caractéristiques cliniques de la cohorte CA

R. Bibliographiques,

W. D. Travis, E. Brambilla, A. G. Nicholson, Y. Yatabe, J. Austin et al., The 2015 World Health Organization Classification of Lung Tumors, J Thorac Oncol. 1 sept, vol.10, issue.9, pp.1243-60, 2015.

D. Swarts, F. Ramaekers, and E. Speel, Molecular and cellular biology of neuroendocrine lung tumors: Evidence for separate biological entities, Biochim Biophys Acta BBA -Rev Cancer. déc, vol.1826, issue.2, pp.255-71, 2012.

M. A. Bakker, S. Willemsen, K. Grünberg, L. A. Noorduijn, M. Van-oosterhout et al., Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability, Histopathology. févr, vol.56, issue.3, pp.356-63, 2010.

T. E. Stinchcombe, Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer, The Oncologist. déc, vol.22, issue.12, pp.1510-1517, 2017.

M. Fasano, D. Corte, C. M. Papaccio, F. Ciardiello, F. Morgillo et al., Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy, J Thorac Oncol. août, vol.10, issue.8, pp.1133-1174, 2015.

G. Pelosi, F. Bianchi, E. Dama, M. Simbolo, A. Mafficini et al., Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm, Virchows Arch. avr, vol.472, issue.4, pp.567-77, 2018.

L. Meder, K. König, L. Ozreti?, A. M. Schultheis, F. Ueckeroth et al., NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas, Int J Cancer. 15 févr, vol.138, issue.4, pp.927-965, 2016.

J. L. Derks, N. Leblay, S. Lantuejoul, A. Dingemans, E. Speel et al., New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management, J Thorac Oncol. juin, vol.13, issue.6, pp.752-66, 2018.

A. M. Quinn, A. Chaturvedi, and D. Nonaka, High-grade Neuroendocrine Carcinoma of the Lung With Carcinoid Morphology: A Study of 12 Cases, Am J Surg Pathol. févr, vol.41, issue.2, pp.263-70, 2017.

G. Pelosi, G. Rindi, W. D. Travis, and M. Papotti, Ki-67 Antigen in Lung Neuroendocrine Tumors: Unraveling a Role in Clinical Practice, J Thorac Oncol. mars, vol.9, issue.3, pp.273-84, 2014.

. Rv-l, G. Ry-o, and J. , WHO Classification of Tumours of Endocrine Organs

D. Sur, Classificat ion-Of-Tumours/Who-Classification-Of-Tumours-Of-Endocrine, 2017.

C. M. Mccall, C. Shi, T. C. Cornish, D. S. Klimstra, L. H. Tang et al., Grading of Well-differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of Both Ki67 Proliferative Index and Mitotic Rate, Am J Surg Pathol, vol.37, issue.11, pp.1671-1678, 2013.

G. Klöppel, D. S. Klimstra, R. H. Hruban, V. Adsay, C. Capella et al., Pancreatic Neuroendocrine Tumors: Update on the New World Health Organization Classification, vol.22, pp.7-29, 2017.

M. Milione, P. Maisonneuve, F. Spada, A. Pellegrinelli, P. Spaggiari et al., The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories, Neuroendocrinology, vol.104, issue.1, pp.85-93, 2017.

N. Raj, E. Valentino, M. Capanu, L. H. Tang, O. Basturk et al., Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated, Pancreas. mars, vol.46, issue.3, pp.296-301, 2017.

M. Peifer, L. Fernández-cuesta, M. L. Sos, J. George, D. Seidel et al., Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer, Nat Genet, vol.44, issue.10, pp.1104-1114, 2012.

J. George, J. S. Lim, S. J. Jang, Y. Cun, L. Ozreti? et al., Comprehensive genomic profiles of small cell lung cancer, Nature. août, vol.524, issue.7563, pp.47-53, 2015.

N. Rekhtman, M. C. Pietanza, M. D. Hellmann, J. Naidoo, A. Arora et al., Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets, Clin Cancer Res Off J Am Assoc Cancer Res. 15 juill, vol.22, issue.14, pp.3618-3647, 2016.

S. Yachida, E. Vakiani, C. M. White, Y. Zhong, T. Saunders et al., Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Welldifferentiated Pancreatic Neuroendocrine Tumors, Am J Surg Pathol. févr, vol.36, issue.2, pp.173-84, 2012.

R. Walter, C. Vollbrecht, C. D. Werner, R. Schmeller, J. Flom et al., Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors, J Cancer, vol.7, issue.15, pp.2165-72, 2016.

Y. Jiao, C. Shi, B. H. Edil, R. F. De-wilde, D. S. Klimstra et al., DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors, Science. 4 mars, vol.331, issue.6021, pp.1199-203, 2011.

A. Pancreatic-cancer-genome-initiative, A. Scarpa, D. K. Chang, K. Nones, V. Corbo et al., Whole-genome landscape of pancreatic neuroendocrine tumours, Nature. mars, vol.543, issue.7643, pp.65-71, 2017.

G. Rindi, D. S. Klimstra, B. Abedi-ardekani, S. L. Asa, F. T. Bosman et al., A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal, Mod Pathol, vol.31, issue.12, pp.1770-86, 2018.

G. Klöppel, Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications, Visc Med, vol.33, pp.324-354, 2017.

, WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart

L. H. Tang, B. R. Untch, D. L. Reidy, E. O'reilly, D. Dhall et al., Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas, Clin Cancer Res. 15 févr, vol.22, issue.4, pp.1011-1018, 2016.

R. F. De-wilde, C. M. Heaphy, A. Maitra, A. K. Meeker, B. H. Edil et al., Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors, Mod Pathol. juill, vol.25, issue.7, pp.1033-1042, 2012.

R. Yadav, A. Kakkar, A. Sharma, P. S. Malik, and M. C. Sharma, Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors

, Scand J Gastroenterol. 2 août, vol.51, issue.8, pp.994-1003, 2016.

E. Wakeam, S. A. Acuna, N. B. Leighl, M. E. Giuliani, S. Finlayson et al., Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival, Lung Cancer. juill, vol.109, pp.78-88, 2017.

F. G. Fernandez and R. J. Battafarano, Large-Cell Neuroendocrine Carcinoma of the Lung: An Aggressive Neuroendocrine Lung Cancer, Semin Thorac Cardiovasc Surg. sept, vol.18, issue.3, pp.206-216, 2006.

W. D. Travis, A. A. Gal, T. V. Colby, D. S. Klimstra, R. Falk et al., Reproducibility of neuroendocrine lung tumor classification, Hum Pathol. mars, vol.29, issue.3, pp.272-281, 1998.

A. M. Marchevsky, A. A. Gal, S. Shah, and M. N. Koss, Morphometry Confirms the Presence of Considerable Nuclear Size Overlap Between "Small Cells" and "Large Cells" in High-Grade Pulmonary Neuroendocrine Neoplasms, Am J Clin Pathol, vol.116, issue.4, pp.466-72, 2001.

M. A. Den-bakker and F. Thunnissen, Neuroendocrine tumours-challenges in the diagnosis and classification of pulmonary neuroendocrine tumours, J Clin Pathol, vol.66, issue.10, pp.862-871, 2013.

A. M. Quinn, A. Chaturvedi, and D. Nonaka, High-grade Neuroendocrine Carcinoma of the Lung With Carcinoid Morphology: A Study of 12 Cases, Am J Surg Pathol. févr, vol.41, issue.2, pp.263-70, 2017.

L. Fernandez-cuesta, M. Peifer, X. Lu, R. Sun, L. Ozreti? et al., Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids, Nat Commun. 27 mars, vol.5, p.3518, 2014.

F. Vélayoudom-céphise, P. Duvillard, L. Foucan, J. Hadoux, C. N. Chougnet et al., Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer, vol.20, pp.649-57, 2013.

M. Heetfeld, C. N. Chougnet, I. H. Olsen, A. Rinke, I. Borbath et al., Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms, Endocr Relat Cancer. août, vol.22, issue.4, pp.657-64, 2015.

A. D. Singhi and D. S. Klimstra, Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases, Histopathology. janv, vol.72, issue.1, pp.168-77, 2018.

L. H. Tang, O. Basturk, J. J. Sue, and D. S. Klimstra, A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas, Am J Surg Pathol. sept, vol.40, issue.9, pp.1192-202, 2016.

T. Takahashi, M. Nau, I. Chiba, M. Birrer, R. Rosenberg et al., p53: a frequent target for genetic abnormalities in lung cancer. Science, vol.246, pp.491-495, 1989.

I. I. Wistuba, A. F. Gazdar, and J. D. Minna, Molecular genetics of small cell lung carcinoma, Semin Oncol. avr, vol.28, issue.2, pp.3-13, 2001.

N. Mori, J. Yokota, T. Akiyama, Y. Sameshima, A. Okamoto et al., Variable mutations of the RB gene in small-cell lung carcinoma, Oncogene. nov, vol.5, issue.11, pp.1713-1720, 1990.

J. George, V. Walter, M. Peifer, L. B. Alexandrov, D. Seidel et al., Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors, Nat Commun, vol.9, issue.13, 2018.

G. Pelosi, A. Sonzogni, S. Harari, A. Albini, E. Bresaola et al., Classification of pulmonary neuroendocrine tumors: new insights. Transl Lung Cancer Res, vol.6, pp.513-542, 2017.

A. E. Walts, D. Ines, and A. M. Marchevsky, Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors, Mod Pathol Off J U S Can Acad Pathol Inc. sept, vol.25, issue.9, pp.1258-64, 2012.

L. H. Tang, M. Gonen, C. Hedvat, I. M. Modlin, and D. S. Klimstra, Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System: A Comparison of Digital Image Analysis With Manual Methods, Am J Surg Pathol. déc, vol.36, issue.12, pp.1761-70, 2012.

M. D. Reid, P. Bagci, N. Ohike, B. Saka, I. E. Seven et al., Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies, Mod Pathol Off J U S Can Acad Pathol Inc. mai, vol.28, issue.5, pp.686-94, 2015.

G. A. Masters, S. Temin, C. G. Azzoli, G. Giaccone, S. Baker et al., Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, vol.33, issue.30, pp.3488-515, 2015.

J. L. Derks, R. J. Van-suylen, E. Thunnissen, M. A. Den-bakker, H. J. Groen et al., Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?, Eur Respir J. juin, vol.49, issue.6, p.1601838, 2017.

J. Naidoo, M. L. Santos-zabala, T. Iyriboz, K. M. Woo, C. S. Sima et al., Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes, Clin Lung Cancer. sept, vol.17, issue.5, pp.121-130, 2016.

P. Christopoulos, W. Engel-riedel, C. Grohé, C. Kropf-sanchen, V. Pawel et al., Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial, Ann Oncol. 1 août, vol.28, issue.8, pp.1898-902, 2017.

, Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome | Clinical Cancer Research